Journal of Pharmacology, Genetics and Molecular Biology (JPGMB)
ISSN: 3049-3757 | Vol. 01, Issue-05, Sep-Oct, 2025

Current Challenges in The Treatment of Autoimmune Disorders

Rakesh Sahebrao Jadhav (PT)[1*], Kalpana Krishnarao Jadhav[2], Milind Mohan Godbole[2], Preeti Dagduji Ghodge (PT)[3], Nilesh V. Dere[4]

[1]Dr. Bhanudas Dere College of Physiotherapy, Sangamner Dist. Ahilyanagar (Maharashtra)
[2]Yashwant Ayurvedic College PGT & RC Kodoli, Tal Panhala Dist Kolhapur (Maharashtra)
[3]RJS College of Physiotherapy, Kopargaon, Dist.Ahilyanagar (Maharashtra)
[4]Sangam Sevabhavi Trust's Ayurved College, Sangamner

***Corresponding Author E-mail: drrakeshsj@gmail.com**

ABSTRACT

The broad and diverse category of chronic diseases known as autoimmune disorders is caused by the body's immune system mistakenly attacking its own cells and tissues, which leads to tissue damage, organ failure, and persistent inflammation. Because of their complex etiology, which includes genetic, environmental, and immunological variables, these disorders—which include multiple sclerosis, rheumatoid arthritis, systemic lupus erythematosus, and type 1 diabetes—present serious therapeutic issues. There has been little progress in creating long-lasting and efficient medicines, even with significant advances in immunology and therapeutic approaches. Understanding the pathophysiology of diseases, assessing immunomodulatory tactics, and forecasting the possible effectiveness of new treatments have all benefited greatly from the use of animal models. This review focuses on the current difficulties in treating autoimmune disorders as they have been identified by animal-based research. These difficulties include species-specific immune responses, translational gaps between preclinical and clinical outcomes, variability in disease manifestation, and limitations of current preclinical models. Additionally, it talks about methodological strategies, the advantages and disadvantages of various animal models, and new discoveries in treatments meant to alter immune responses.

Key Words:

Keywords: Autoimmune Disorders, Animal Models, Immunotherapy, Disease Pathophysiology, Systemic Lupus Erythematosus, Type 1 Diabetes, Therapeutic Challenges, Immunomodulation.

Article History:

Received on July 29, 2025

Revised on Aug 29, 2025

Accepted on Sep 28, 2025

Published on Oct 14, 2025

DOI: https://doi.org/10.64062/JPGMB.Vol1.Issue5.7

1. INTRODUCTION

The immune system mistakenly attacks the body's own cells and tissues in autoimmune disorders, a broad and complicated category of chronic illnesses that include ongoing inflammation, progressive tissue damage, and compromised organ function[1]. From organ-specific illnesses like type 1 diabetes (T1D) and autoimmune thyroiditis to systemic problems like systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA), these disorders include

a broad range of clinical symptoms. Another well-known autoimmune disease, multiple sclerosis (MS), mostly affects the central nervous system, leading to neurological impairment and demyelination. Together, these illnesses impact millions of people worldwide and pose serious social, psychological, and economic obstacles, adding to the overall health burden.

Autoimmune diseases have a complicated pathophysiology that involves the interaction of environmental variables, genetic vulnerability, and dysregulated immune responses[2]. Environmental triggers like infections, dietary factors, and exposure to toxins can hasten the onset of disease in genetically susceptible individuals, while genetic predisposition, such as specific human leukocyte antigen (HLA) alleles and non-HLA gene variants, has been demonstrated to increase the likelihood of autoimmunity. Disease development is further aggravated by dysregulation of both innate and adaptive immunological responses, which includes abnormal activation of autoreactive T and B cells, loss of self-tolerance, and overproduction of pro-inflammatory cytokines[3].

Developing effective cures for autoimmune diseases is still a significant issue, even with significant advancements in immunology, molecular biology, and biomedical research. Instead of attaining long-term remission or total disease reversal, current therapy approaches primarily aim to reduce symptoms, alter immune system activity, and slow the course of the illness. Immunosuppressive medications, corticosteroids, and biologic medicines that target particular immunological pathways are examples of conventional therapy; nevertheless, these treatments are frequently linked to side effects and inconsistent patient responses. The inherent complexity and variability of autoimmune disorders restrict the general clinical translation of emerging methods like targeted biologics, gene therapy, and personalized medicine, which hold promise for more accurate and efficient care[4].



Figure 1

1.1. Background of the Study

Over the past few decades, the frequency of autoimmune illnesses has been rising significantly worldwide, leading to high rates of morbidity, permanent disability, and large financial and medical costs[5]. Because of the need for ongoing care, frequent hospital stays, and long-term usage of immunosuppressive or biologic medications, these conditions not only lower quality of life but also place a significant financial burden on healthcare systems. Because patients frequently show significant variety in disease onset, symptom intensity, progression, and response to treatment, the heterogeneity of autoimmune disorders makes therapeutic management of these conditions even more challenging. For instance, people with systemic lupus erythematosus (SLE) may respond differently to treatment, and some may have modest flare-ups while others may have potentially fatal organ involvement[6].

The development of targeted and efficient therapeutic strategies depends on an understanding of the underlying immunopathogenesis of these illnesses. Genetic predisposition, environmental stimuli, and dysregulated immune responses—such as the breakdown of self-tolerance, autoreactive cell activation, and cytokine imbalance—interplay intricately to cause autoimmune disorders[7]. However, considerable genetic and environmental diversity across patient populations, as well as ethical concerns including the risk of intrusive procedures and long-term drug exposure, frequently limit the potential to advance this understanding through human studies. Direct investigation of disease mechanisms in people is further limited by practical difficulties in accessing damaged tissues, such as central nervous system tissue in multiple sclerosis or pancreatic islets in type 1 diabetes[8].

In order to analyze molecular pathways and immunological dysregulation in autoimmune illnesses, these constraints have prompted the employment of alternate research methodologies, such as in vitro models, organoids, and animal models[9]. The intricacy of human autoimmunity, however, cannot be adequately captured by a single model, underscoring the pressing need for novel experimental designs, the incorporation of multi-omics data, and the creation of tailored treatment plans. Therefore, to improve the diagnosis, treatment, and eventually prevention of autoimmune illnesses, a thorough understanding of disease heterogeneity, immunopathogenesis, and patient-specific variables is crucial[10].

Table 1: Common Animal Models for Autoimmune Disorders

Autoimmune Disorder	Animal Model	Key Features	Limitations
Type 1 Diabetes (T1D)	Non-Obese Diabetic (NOD) mice	Spontaneous autoimmune β-cell destruction	Does not capture full human disease heterogeneity
Multiple Sclerosis (MS)	Experimental Autoimmune Encephalomyelitis (EAE)	T-cell mediated demyelination, acute and relapsing-remitting phases	Fails to model progressive MS stages

Rheumatoid Arthritis (RA)	Collagen-Induced Arthritis (CIA)	Joint inflammation, cartilage destruction	Inadequate replication of chronic joint damage
Systemic Lupus Erythematosus (SLE)	MRL/lpr mice, NZB/W F1 mice	Immune complex deposition, renal complications	High variability, limited multi-organ involvement

In this regard, studies of autoimmune diseases have come to rely heavily on animal-based research[11]. Comprehensive studies of immunological mechanisms, genetic contributions, and environmental influences on disease development have been made possible by preclinical models, such as MRL/lpr mice for SLE, Experimental Autoimmune Encephalomyelitis (EAE) for MS, and Non-Obese Diabetic (NOD) mice for T1D. Prior to human clinical trials, these models offer a controlled environment for assessing therapeutic interventions, comprehending immune cell dynamics, and testing cutting-edge immunomodulatory techniques. Animal-based research continues to be crucial in determining how we understand and treat autoimmune diseases by connecting mechanistic findings with possible therapeutic applications.

1.2. Objectives of the Review:

1. To evaluate the current challenges in the treatment of autoimmune disorders as revealed through animal-based studies.

2. To critically analyse the strengths and limitations of existing animal models in predicting therapeutic outcomes.

3. To identify gaps in preclinical research and propose future directions for improving translational relevance in autoimmune therapy.

1.3. Importance of the Topic:

To further translational research in autoimmune illnesses, a thorough grasp of the benefits and drawbacks of animal models is essential. Testing the effectiveness and safety of new treatment drugs, figuring out important genetic and molecular pathways, and deciphering the intricate mechanisms causing immunological dysregulation have all benefited greatly from the use of animal models[12]. However, species-specific variations, variations in illness manifestation, and partial replication of human pathophysiology sometimes limit the predictive utility of these models for human disease outcomes.

This review aims to offer a comprehensive and integrated viewpoint that emphasizes the advantages and disadvantages of the current preclinical models by critically assessing the state of animal-based autoimmune research. Future experimental design can be guided by this kind of analysis, which guarantees that models are selected and applied in a way that optimizes their relevance to human disease[13]. Additionally, by being aware of these constraints, scientists will be able to enhance and supplement conventional animal research with cutting-edge techniques like organoid systems, humanized mice, and computer modeling, ultimately increasing the translational potential of preclinical results[14]. The goal of this thorough assessment is to help guide the creation of safe, efficient, and focused treatment plans, closing the gap between

clinical practice and experimental research and hastening the development of curative treatments for autoimmune diseases[15].

Table 2: Summary of Literature on Current Challenges in the Treatment of Autoimmune Disorders

Author Name	Topic Covered	Research Study Title
Tavakolpour, S. (2017)[16]	Personalized medicine in autoimmune diseases; opportunities and challenges	Towards personalized medicine for patients with autoimmune diseases: opportunities and challenges
Sindhu, R. K., Madaan, P., Chandel, P., Akter, R., Adilakshmi, G., & Rahman, M. H. (2022)[17]	Gene therapy approaches for autoimmune disorder management; prospects and challenges	Therapeutic approaches for the management of autoimmune disorders via gene therapy: prospects, challenges and opportunities
Miller, F. W. (2023)[18]	Prevalence, understanding, diagnosis, treatment, and prevention of autoimmune diseases	The increasing prevalence of autoimmunity and autoimmune diseases: an urgent call to action for improved understanding, diagnosis, treatment, and prevention
Song, Y., Li, J., & Wu, Y. (2024)[19]	Mechanisms of autoimmunity and novel therapeutic strategies	Evolving understanding of autoimmune mechanisms and new therapeutic strategies of autoimmune disorders
Albarbar, B., & Aga, H. (2024)[20]	Recent advances and future perspectives in autoimmune disease research	A review on autoimmune diseases: Recent advances and future perspectives
Morton Cuthrell, K., Tzenios, N., & Umber, J. (2022)[21]	Burden, prevalence, and impact of autoimmune disorders	Burden of Autoimmune Disorders; a review

2. Challenges in Modeling Autoimmune Disorders in Animals

Because of the inherent complexity and variety of the human immune system, creating accurate and trustworthy animal models for autoimmune illnesses remains a significant problem. The start, course, and severity of autoimmune disorders are determined by a dynamic interaction between genetic predisposition, environmental factors, and complex immune regulatory mechanisms[22]. It is challenging to capture the whole range of human illness phenotypes because no single animal model can accurately duplicate these complex processes. For

instance, because Non-Obese Diabetic (NOD) mice consistently exhibit autoimmune destruction of pancreatic β-cells, simulating the autoimmune component of the disease, NOD mice have been used extensively to investigate type 1 diabetes. Nevertheless, the whole heterogeneity seen in human patients—including differences in the course of the disease, the age at which it first manifests, and the reactions to treatment—is not fully reflected in NOD mice[23].

Species-specific immunological responses represent an additional constraint. In important areas of immunity, such as cytokine signaling, the makeup and function of immune cell subsets, and regulatory pathways that sustain immunological tolerance, rats—the most widely used animal models—differ from humans. The translational significance of preclinical findings may be diminished as a result of these interspecies variations, which may result in disparities in disease processes and treatment responses[24].

Furthermore, environmental and genetic heterogeneity provide serious difficulties. Usually, laboratory animals are kept in extremely controlled environments with standardized housing, consistent food, and little exposure to environmental allergens[25]. The numerous environmental, microbiological, and behavioral elements that affect the onset and progression of human autoimmune diseases are not captured by these settings, despite the fact that they lessen experimental variability. In laboratory settings, variables that are crucial in regulating human immune responses—such as infections, nutrition, microbiome composition, and stress levels—are frequently absent or drastically altered.



Figure 2: Animal models for autoimmune disorder

Therefore, animal models cannot accurately predict clinical results, even if they are very useful for mechanistic research and for evaluating possible therapy approaches in a controlled setting[26]. Translational failures, in which treatments that work in animal research fail in human

trials, highlight the need for improved preclinical models that better replicate human immunopathology and supplementary strategies like organoid systems, humanized mouse models, and computer modeling to increase predictive value.

3. METHODOLOGICAL APPROACHES AND FINDINGS

Animal models for autoimmune disorders are broadly classified into induced models and spontaneous models, each with unique advantages and limitations.

- Induced Models: These entail purposefully causing illness via chemical inducement or vaccination. For instance, multiple sclerosis is frequently modeled using Experimental Autoimmune Encephalomyelitis (EAE). High repeatability and controlled testing are made possible by induced models, however they frequently oversimplify intricate human disease mechanisms such tissue-specific immune responses and chronic progression.

- Spontaneous Models: Due to a genetic predisposition, autoimmune diseases spontaneously occur in these models, such as MRL/lpr mice for systemic lupus erythematosus. In addition to offering insight into the interplay between genes and the immune system, spontaneous models more closely resemble the course of autoimmunity. They hinder the consistency of experiments, though, due to their great variability and unpredictability in disease onset and severity.

Animal models used for therapeutic trials have provided important new information on the effectiveness and drawbacks of existing therapies:

- Immunosuppressive drugs, such as cyclosporine and corticosteroids, demonstrate potent efficacy in reducing autoimmune activity in animal models but are associated with toxicity and limited long-term benefits.

- Biologic therapies, including anti-TNF and IL-6 inhibitors, show promise in models of rheumatoid arthritis but display variable outcomes across different species, highlighting translational challenges when moving from animals to humans.

Table 2: Comparison of Induced vs. Spontaneous Models

Feature	Induced Models	Spontaneous Models
Disease Initiation	Triggered by immunization or chemicals	Develops naturally due to genetic predisposition
Reproducibility	High	Variable
Disease Mechanisms	May oversimplify human disease	Closer to natural disease course
Examples	EAE for MS, CIA for RA	NOD mice for T1D, MRL/lpr mice for SLE

Strengths	Controlled, predictable onset	Mimics natural immune dysregulation
Limitations	Limited heterogeneity	Variability, unpredictable onset

4. STRENGTHS AND WEAKNESSES OF ANIMAL-BASED RESEARCH

Strengths:

1. **Controlled Mechanistic Studies:** Animal models enable precise manipulation of genetic and immunological factors, allowing researchers to dissect complex pathways of autoimmune pathogenesis.
2. **Preclinical Therapeutic Evaluation:** Novel drugs and biologics can be systematically tested for efficacy and safety before progressing to clinical trials.
3. **Genetic Insights:** Transgenic and knockout models help identify the roles of specific genes in autoimmune disease development and progression.

Weaknesses:

1. **Over-Reliance on Murine Models:** Excessive dependence on mice limits the diversity of findings and may overlook disease mechanisms present in other species.
2. **Poor Predictability of Clinical Outcomes:** Therapies successful in animal models often **fail in humans** due to interspecies differences in immune responses and disease manifestation.
3. **Ethical Considerations:** Certain experimental procedures are ethically restricted, limiting the scope of research in animal models.

4. Thematic Analysis of Autoimmune Disorders

a. Multiple Sclerosis (MS)

- **Animal Model:** Experimental Autoimmune Encephalomyelitis (EAE) in rodents.
- **Findings:** EAE has provided valuable insights into T-cell mediated demyelination, inflammatory pathways, and the testing of immunomodulatory drugs such as interferons and monoclonal antibodies.
- **Challenges:** EAE predominantly models the acute and relapsing-remitting stages of MS and fails to replicate progressive disease stages, limiting its utility for developing therapies targeting chronic neurodegeneration.

b. Rheumatoid Arthritis (RA)

- **Animal Model:** Collagen-Induced Arthritis (CIA) in mice and rats.
- **Findings:** CIA models are extensively used to study joint inflammation, synovial hyperplasia, and the effects of biologic therapies like anti-TNF and IL-6 inhibitors.

- **Challenges:** These models inadequately reproduce the chronic joint destruction and systemic features observed in human RA, constraining the translational relevance of therapeutic findings.

c. Systemic Lupus Erythematosus (SLE)

- **Animal Models:** MRL/lpr mice and NZB/W F1 mice.
- **Findings:** Spontaneous SLE models have facilitated the study of immune complex deposition, glomerulonephritis, and autoimmune antibody production.
- **Challenges:** High variability in disease onset and severity, combined with incomplete replication of multi-organ involvement, limits the predictive power of these models.

d. Type 1 Diabetes (T1D)

- **Animal Model:** Non-Obese Diabetic (NOD) mice.
- **Findings:** NOD mice have been instrumental in understanding β-cell specific immune attacks, testing immunotherapies, and studying environmental triggers of disease.
- **Challenges:** Translational success is limited due to species-specific differences in pancreatic β-cell biology and immune regulation, often resulting in discrepancies between preclinical efficacy and human clinical outcomes.

Table 4: Strengths and Limitations of Animal-Based Research

Aspect	Strengths	Limitations
Mechanistic Studies	Controlled experimental conditions, allows genetic and immunological manipulation	May not replicate full human disease complexity
Therapeutic Testing	Enables preclinical evaluation of drugs, biologics, and experimental therapies	Poor predictability of human clinical outcomes
Genetic Insights	Transgenic and knockout models reveal gene functions in autoimmunity	Over-reliance on murine models limits diversity
Ethical Considerations	Provides valuable insights while following ethical guidelines	Certain experiments restricted, limiting scope

5. DISCUSSION

Research involving animals has been crucial in improving our comprehension of the mechanisms underlying autoimmune diseases and assessing possible treatment approaches[27]. Important insights into immune cell dysregulation, cytokine signaling, and genetic contributions to autoimmunity have been gained from preclinical models, such as NOD mice

for type 1 diabetes, EAE mice for multiple sclerosis, CIA mice for rheumatoid arthritis, and MRL/lpr mice for systemic lupus erythematosus[28]. The basis of autoimmune research has been shaped by these models, which have made it possible to evaluate immunosuppressive medications, biologics, and experimental treatments systematically before they go through clinical trials[29].

5.1. Interpretation and Analysis of Findings

Notwithstanding their benefits, animal models have serious drawbacks when it comes to simulating autoimmune diseases in humans. Given interspecies variations in immune system architecture, genetic background, and illness progression, no single model can adequately represent the complexity of human disease[30]. Interpretation is made more difficult and reproducibility is diminished by model-to-model variation in disease manifestation and treatment outcomes. Furthermore, there is a recurring translational gap: treatments that show promise in animal research frequently fall short in human clinical trials. These findings show that whereas animal models work well for mechanistic research, they have little predictive power for clinical outcomes[31].

5.2. Implications and Significance

The development of treatments is significantly impacted by the shortcomings of research involving animals. The majority of the current therapies for autoimmune diseases are palliative in nature, with the goal of reducing abnormal immune activity and managing symptoms rather than offering permanent remission or a cure[32]. Therapeutic innovation may be slowed by an over-reliance on traditional animal models since the mechanistic insights obtained from these models might not adequately represent the complexity and variability of autoimmune diseases in humans. In order to convert preclinical discoveries into successful clinical therapies, these gaps must be filled[33].

These constraints can be addressed with the use of creative solutions. To evaluate immunotherapies, for example, humanized mouse models that include human immune cells or tissues offer a more translationally applicable system. Similarly, in vitro controlled studies of human-specific immunological interactions are made possible by 3D organoid and tissue-on-chip technologies[34]. By simulating disease progression, immunological responses, and therapeutic outcomes, integrating computer modeling and systems biology techniques might further improve predictive accuracy and facilitate better decision-making in preclinical research.

5.3. Gaps and Future Research Directions

To improve the **translational impact and scientific rigor** of autoimmune research, several strategies are recommended:

1. **Development of multi-species models:** Using a broader range of animal species may better capture disease heterogeneity and uncover conserved immune mechanisms relevant to humans.

2. **Expansion of humanized immune system models:** These models can bridge species-specific gaps and increase the predictive value of preclinical findings.

3. **Integration of omics technologies and bioinformatics:** Combining genomics, proteomics, and metabolomics with computational analysis can provide precision insights into disease pathways, identify biomarkers, and uncover novel therapeutic targets.

4. **Ethical refinement following the "3Rs" principle:** Emphasizing Replacement, Reduction, and Refinement ensures humane treatment of animals while enhancing the quality and reliability of research data.

To sum up, research involving animals is still essential to comprehending autoimmune diseases[35]. However, to get beyond present obstacles, enhance translational relevance, and direct the creation of safe, efficient, and focused treatments for autoimmune disorders, creative modeling approaches, cutting-edge analytical tools, and ethical improvement are crucial[36,37].

6. CONCLUSION

Research on autoimmune disorders still relies heavily on animal models, which offer vital information about immunological dysregulation, disease processes, and possible treatment approaches[38]. In order to analyze complex immunological pathways and assess the effectiveness of new treatments in a controlled experimental setting, researchers have studied models such as NOD mice for type 1 diabetes, EAE mice for multiple sclerosis, CIA mice for rheumatoid arthritis, and MRL/lpr mice for systemic lupus erythematosus. These models' drawbacks, including as species-specific immunological variations, variation in illness presentation, and insufficient replication of human pathophysiology, highlight the translational gaps that frequently impede the creation of successful therapeutic treatments. These difficulties underscore the need for improved preclinical approaches that enhance prediction reliability and more closely mirror the mechanisms behind real autoimmune diseases[39]. The review promotes integrative and creative methods to improve translational relevance while highlighting the ongoing significance of animal-based research. These tactics include the creation of humanized immune system models to fill in species-specific gaps, the use of a variety of animal models to capture disease heterogeneity, and a concentrated effort to convert mechanistic insights into results that may be applied therapeutically[40].

6.1. Importance of the Review

This review is important because it summarizes the state of the art regarding the use of animal models in autoimmune research, points out present drawbacks, and highlights methods to increase translational relevance. The review offers recommendations for creating preclinical research that is more predictive of human outcomes and aids in the creation of safer and more efficient treatments by combining findings from various models and methodologies.

Additionally, the review promotes creative and integrative methods, like using a variety of animal models, creating humanized immune system models, and concentrating on connecting mechanistic understanding with clinical results.

6.2. Recommendations:

- Employ diverse animal models to reduce reliance on a single system and capture broader disease variability.

- Advance humanized and multi-species models to strengthen the translational potential of preclinical findings.

- Direct research toward bridging mechanistic insights with clinical applicability, ensuring that discoveries in animal models can inform the development of safe, effective, and targeted therapies for autoimmune disorders.

In summary, while animal models remain indispensable for understanding autoimmune diseases, the integration of innovative modelling techniques, ethical refinement, and translational focus will be essential to overcoming current challenges and accelerating the development of effective treatments for these complex disorders.

REFERENCES

1. Wang, L., Wang, F. S., & Gershwin, M. E. (2015). Human autoimmune diseases: a comprehensive update. *Journal of internal medicine*, *278*(4), 369-395.
2. Fugger, L., Jensen, L. T., & Rossjohn, J. (2020). Challenges, progress, and prospects of developing therapies to treat autoimmune diseases. *Cell*, *181*(1), 63-80.
3. Schwartz, D. M., Bonelli, M., Gadina, M., & O'shea, J. J. (2016). Type I/II cytokines, JAKs, and new strategies for treating autoimmune diseases. *Nature Reviews Rheumatology*, *12*(1), 25-36.
4. Yadav, K., Pradhan, M., Singh, D., & Singh, M. R. (2022). Targeting autoimmune disorders through metal nanoformulation in overcoming the fences of conventional treatment approaches. In *Translational autoimmunity* (pp. 361-393). Academic Press.
5. Eggenhuizen, P. J., Ng, B. H., & Ooi, J. D. (2020). Treg enhancing therapies to treat autoimmune diseases. *International journal of molecular sciences*, *21*(19), 7015.
6. Xue, C., Yao, Q., Gu, X., Shi, Q., Yuan, X., Chu, Q., ... & Li, L. (2023). Evolving cognition of the JAK-STAT signaling pathway: autoimmune disorders and cancer. *Signal transduction and targeted therapy*, *8*(1), 204.
7. Conrad, N., Verbeke, G., Molenberghs, G., Goetschalckx, L., Callender, T., Cambridge, G., ... & Verbakel, J. Y. (2022). Autoimmune diseases and cardiovascular risk: a population-based study on 19 autoimmune diseases and 12 cardiovascular diseases in 22 million individuals in the UK. *The Lancet*, *400*(10354), 733-743.
8. Lundin, K. E., & Wijmenga, C. (2015). Coeliac disease and autoimmune disease—genetic overlap and screening. *Nature reviews Gastroenterology & hepatology*, *12*(9), 507-515.
9. Banerjee, S., Biehl, A., Gadina, M., Hasni, S., & Schwartz, D. M. (2017). JAK–STAT signaling as a target for inflammatory and autoimmune diseases: current and future prospects. *Drugs*, *77*(5), 521-546.
10. Cho, J. H., & Feldman, M. (2015). Heterogeneity of autoimmune diseases: pathophysiologic insights from genetics and implications for new therapies. *Nature medicine*, *21*(7), 730-738.
11. Raphael, I., Joern, R. R., & Forsthuber, T. G. (2020). Memory CD4+ T cells in immunity and autoimmune diseases. *Cells*, *9*(3), 531.
12. Pisetsky, D. S. (2023). Pathogenesis of autoimmune disease. *Nature Reviews Nephrology*, *19*(8), 509-524.

13. Mazzone, R., Zwergel, C., Artico, M., Taurone, S., Ralli, M., Greco, A., & Mai, A. (2019). The emerging role of epigenetics in human autoimmune disorders. *Clinical epigenetics*, *11*(1), 34.
14. Ayala-Fontánez, N., Soler, D. C., & McCormick, T. S. (2016). Current knowledge on psoriasis and autoimmune diseases. *Psoriasis: Targets and Therapy*, 7-32.
15. Rosenblum, M. D., Remedios, K. A., & Abbas, A. K. (2015). Mechanisms of human autoimmunity. *The Journal of clinical investigation*, *125*(6), 2228-2233.
16. Tavakolpour, S. (2017). Towards personalized medicine for patients with autoimmune diseases: opportunities and challenges. *Immunology letters*, *190*, 130-138.
17. Sindhu, R. K., Madaan, P., Chandel, P., Akter, R., Adilakshmi, G., & Rahman, M. H. (2022). Therapeutic approaches for the management of autoimmune disorders via gene therapy: prospects, challenges and opportunities. *Current Gene Therapy*, *22*(3), 245-261.
18. Miller, F. W. (2023). The increasing prevalence of autoimmunity and autoimmune diseases: an urgent call to action for improved understanding, diagnosis, treatment, and prevention. *Current opinion in immunology*, *80*, 102266.
19. Song, Y., Li, J., & Wu, Y. (2024). Evolving understanding of autoimmune mechanisms and new therapeutic strategies of autoimmune disorders. *Signal Transduction and Targeted Therapy*, *9*(1), 263.
20. Albarbar, B., & Aga, H. (2024). A review on autoimmune diseases: Recent advances and future perspectives. *AlQalam Journal of Medical and Applied Sciences*, 718-729.
21. Morton Cuthrell, K., Tzenios, N., & Umber, J. (2022). Burden of Autoimmune Disorders; a review. *Asian Journal of Immunology*, *6*(3), 1-3.
22. Jang, D. I., Lee, A. H., Shin, H. Y., Song, H. R., Park, J. H., Kang, T. B., ... & Yang, S. H. (2021). The role of tumor necrosis factor alpha (TNF-α) in autoimmune disease and current TNF-α inhibitors in therapeutics. *International journal of molecular sciences*, *22*(5), 2719.
23. Müller, F., Taubmann, J., Bucci, L., Wilhelm, A., Bergmann, C., Völkl, S., ... & Schett, G. (2024). CD19 CAR T-cell therapy in autoimmune disease—a case series with follow-up. *New England Journal of Medicine*, *390*(8), 687-700.
24. Farh, K. K. H., Marson, A., Zhu, J., Kleinewietfeld, M., Housley, W. J., Beik, S., ... & Bernstein, B. E. (2015). Genetic and epigenetic fine mapping of causal autoimmune disease variants. *Nature*, *518*(7539), 337-343.
25. Chang, R., Chen, T. Y. T., Wang, S. I., Hung, Y. M., Chen, H. Y., & Wei, C. C. J. (2023). Risk of autoimmune diseases in patients with COVID-19: a retrospective cohort study. *EClinicalMedicine*, *56*.
26. Hofmann, K., Clauder, A. K., & Manz, R. A. (2018). Targeting B cells and plasma cells in autoimmune diseases. *Frontiers in immunology*, *9*, 835.
27. McLean, M. H., Dieguez, D., Miller, L. M., & Young, H. A. (2015). Does the microbiota play a role in the pathogenesis of autoimmune diseases?. *Gut*, *64*(2), 332-341.
28. Du, F. H., Mills, E. A., & Mao-Draayer, Y. (2017). Next-generation anti-CD20 monoclonal antibodies in autoimmune disease treatment. *Autoimmunity Highlights*, *8*(1), 12.
29. Yazar, S., Alquicira-Hernandez, J., Wing, K., Senabouth, A., Gordon, M. G., Andersen, S., ... & Powell, J. E. (2022). Single-cell eQTL mapping identifies cell type–specific genetic control of autoimmune disease. *Science*, *376*(6589), eabf3041.
30. Luo, X., Miller, S. D., & Shea, L. D. (2016). Immune tolerance for autoimmune disease and cell transplantation. *Annual review of biomedical engineering*, *18*(1), 181-205.

31. Romano, M., Fanelli, G., Albany, C. J., Giganti, G., & Lombardi, G. (2019). Past, present, and future of regulatory T cell therapy in transplantation and autoimmunity. *Frontiers in immunology*, *10*, 43.
32. Penberthy, J. K., Chhabra, D., Avitabile, N., Penberthy, J. M., Le, N., Xu, Y. R., ... & Hubbard, L. (2018). Mindfulness based therapies for autoimmune diseases and related symptoms. *OBM Integrative and Complementary Medicine*, *3*(4), 1-28.
33. Krienke, C., Kolb, L., Diken, E., Streuber, M., Kirchhoff, S., Bukur, T., ... & Sahin, U. (2021). A noninflammatory mRNA vaccine for treatment of experimental autoimmune encephalomyelitis. *Science*, *371*(6525), 145-153.
34. Stafford, I. S., Kellermann, M., Mossotto, E., Beattie, R. M., MacArthur, B. D., & Ennis, S. (2020). A systematic review of the applications of artificial intelligence and machine learning in autoimmune diseases. *NPJ digital medicine*, *3*(1), 30.
35. Song, H., Fang, F., Tomasson, G., Arnberg, F. K., Mataix-Cols, D., De La Cruz, L. F., ... & Valdimarsdóttir, U. A. (2018). Association of stress-related disorders with subsequent autoimmune disease. *Jama*, *319*(23), 2388-2400.
36. Leonardi, G. C., Gainor, J. F., Altan, M., Kravets, S., Dahlberg, S. E., Gedmintas, L., ... & Awad, M. M. (2018). Safety of programmed death–1 pathway inhibitors among patients with non–small-cell lung cancer and preexisting autoimmune disorders. *Journal of Clinical Oncology*, *36*(19), 1905-1912.
37. Kelly, P. N., Romero, D. L., Yang, Y., Shaffer III, A. L., Chaudhary, D., Robinson, S., ... & Staudt, L. M. (2015). Selective interleukin-1 receptor–associated kinase 4 inhibitors for the treatment of autoimmune disorders and lymphoid malignancy. *Journal of Experimental Medicine*, *212*(13), 2189-2201.
38. Zhao, Q. (2020). Bispecific antibodies for autoimmune and inflammatory diseases: clinical progress to date. *BioDrugs*, *34*(2), 111-119.
39. Johnson, D. B., Sullivan, R. J., Ott, P. A., Carlino, M. S., Khushalani, N. I., Ye, F., ... & Clark, J. I. (2016). Ipilimumab therapy in patients with advanced melanoma and preexisting autoimmune disorders. *JAMA oncology*, *2*(2), 234-240.
40. Wrobleski, S. T., Moslin, R., Lin, S., Zhang, Y., Spergel, S., Kempson, J., ... & Weinstein, D. S. (2019). Highly selective inhibition of tyrosine kinase 2 (TYK2) for the treatment of autoimmune diseases: discovery of the allosteric inhibitor BMS-986165. *Journal of medicinal chemistry*, *62*(20), 8973-8995.